Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Just results
Hims would tell you its business case is simple: GLP-1 demand vastly outpaces supply, and it wants to offer weight loss solutions and expanded access to GLP-1 medications to its subscribers
Our team focuses on personalized wellness support, helping patients explore options that align with their health goals, lifestyle preferences, and medical history
1 In May 2022, Tirzepatide, the world's first GLP-1R/GIPR dual-target agonist, was approved for marketing
US$ 21.05
US$ 22.77
US$ 23.40
US$ 26.01
US$ 21.18
US$ 28.52
US$ 21.80
US$ 26.05
US$ 28.96
